Cerus Co. (NASDAQ:CERS) Position Boosted by Creative Planning

Creative Planning lifted its stake in shares of Cerus Co. (NASDAQ:CERS) by 51.3% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 24,809 shares of the biotechnology company’s stock after purchasing an additional 8,411 shares during the period. Creative Planning’s holdings in Cerus were worth $43,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. SG Americas Securities LLC acquired a new stake in shares of Cerus in the third quarter valued at approximately $121,000. Algert Global LLC acquired a new position in Cerus in the 2nd quarter worth approximately $97,000. The Manufacturers Life Insurance Company lifted its position in Cerus by 10.9% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 73,372 shares of the biotechnology company’s stock worth $129,000 after buying an additional 7,209 shares in the last quarter. AQR Capital Management LLC lifted its position in Cerus by 938.5% in the 2nd quarter. AQR Capital Management LLC now owns 215,901 shares of the biotechnology company’s stock worth $380,000 after buying an additional 195,112 shares in the last quarter. Finally, Hood River Capital Management LLC lifted its stake in shares of Cerus by 390.4% in the 2nd quarter. Hood River Capital Management LLC now owns 1,469,754 shares of the biotechnology company’s stock valued at $2,587,000 after purchasing an additional 1,170,060 shares during the last quarter. Institutional investors and hedge funds own 78.37% of the company’s stock.

Insiders Place Their Bets

In other news, CFO Kevin Dennis Green sold 28,385 shares of the business’s stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $2.18, for a total transaction of $61,879.30. Following the transaction, the chief financial officer now owns 590,365 shares in the company, valued at approximately $1,286,995.70. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 3.40% of the company’s stock.

Cerus Stock Down 1.6 %

Cerus stock opened at $1.86 on Thursday. The firm has a market cap of $345.42 million, a price-to-earnings ratio of -16.91 and a beta of 1.20. The company has a debt-to-equity ratio of 1.19, a current ratio of 2.59 and a quick ratio of 1.92. Cerus Co. has a fifty-two week low of $1.38 and a fifty-two week high of $2.59. The firm has a fifty day moving average price of $1.79 and a two-hundred day moving average price of $1.92.

Wall Street Analyst Weigh In

Separately, Stifel Nicolaus reduced their price objective on shares of Cerus from $6.00 to $3.00 and set a “buy” rating for the company in a research note on Thursday, October 17th.

About Cerus

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.